The departure came the same day that a drugmaker connected to one of Dr. George Tidmarsh’s former business associates filed a ...

The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...

The FDA said it proposed significant changes to simplify biosimilarity studies and reduce what it described as unnecessary ...

George Tidmarsh, the FDA's top drug regulator, has been placed on leave after being accused of abusing his regulatory ...